Aripiprazole Tablet
Product Images NDC 70518-2150

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 5mg 70518 2150 02

This is information about Aripiprazole 5mg tablets. The quantity is 30 tablets. The tablets are pink in color and come in a rectangle shape. The medication is repackaged by RemedyRepack Inc. with contact information provided. The manufacturer is Alembic Pharma. The recommended storage temperature is 20-25°C (77-88°F) with excursions permitted to 15-30°C (59-86°F). Keep the medication out of reach of children.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

FDA Label Image

Aripiprazole Fig 6

This text presents data related to a clinical trial investigating the proportion of subjects with relapse over different days from randomization for Aripiprazole 0.9 compared to Placebo. The number of subjects at risk is provided for each group at various time points. This information is valuable in assessing the efficacy and safety of Aripiprazole in preventing relapse compared to placebo in a clinical setting.*

FDA Label Image

Aripiprazole Fig 9

This text provides a graph showing the Least-Squares Mean Change in YGTSS Total TIC Score over weeks of treatment for Aripiprazole Low, Aripiprazole High, and Placebo.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

This text appears to show a comparison between Aripiprazole and a placebo in terms of the proportion of subjects experiencing relapse over time, as well as the number of subjects at risk at different time points. The data is presented in a tabular format with the number of subjects at risk for each medication at different time intervals, and the days from randomization. The text provides important information for evaluating the effectiveness of Aripiprazole compared to a placebo in preventing relapse.*

FDA Label Image

Aripiprazole Figure1

Effect of Other Drugs on Aripiprazole The text presents information regarding the effects of various drugs on Aripiprazole. It includes details on the fold change and 90% confidence interval for Aripiprazole when interacting with different types of drugs such as CYP1A inhibitor, CYP2D6 inhibitor, and Gastric Acid Blockers. Additionally, it mentions the influence of other drugs like ketoconazole, suinkdine, carbamazepine, famodine, and valproate on the concentration and absorption of Aripiprazole relative to the reference state without any interacting drugs.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

This text mentions the effect of other drugs on Aripiprazole, including substances like CYP3A4 inducers, famotidine, valproate, St. John's Wort, lorazepam, and others. The document indicates changes in relation to the reference state when these interacting drugs are present.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

This text provides information on different special population groups such as poor metabolizers, gender, age categories (<18 and >65 years old), hepatic impairment levels, and renal impairment levels. It also seems to mention a fold change and relative change data related to Aripiprazole.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

FDA Label Image

Structure (Aripiprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.